On page 776, in the paragraph that begins “Allogeneic hematopoietic stem cell transplantation,” “azacitidine” should read “decitabine” in both places where it appears in the passage “A recent phase 3 trial failed to show superiority of azacitidine in improving event-free survival (death, AML transformation, or progression) compared with hydroxyurea in proliferative CMML, due to toxicity.7 Patients treated with hydroxyurea had numerically longer median overall survival (21.9 months) compared with those treated with azacitidine (18.4 months, P = .67).7”
On the same page, in the paragraph that begins “This latest model,” the sentence “There was still a value for including molecular and cytogenetic abnormalities to help guide decision-making in non-high-risk patients, as the presence of high-risk mutations or patients with unfavorable karyotypes identified in the low-risk group who demonstrated a more aggressive disease course” should read “There was still a value for including molecular and cytogenetic abnormalities to help guide decision-making in non-high-risk patients, as the presence of high-risk mutations or an unfavorable karyotype identified patients in the low-risk group who demonstrated a more aggressive disease course.”
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal